Provided by Tiger Trade Technology Pte. Ltd.

Revolution Medicines, Inc.

78.92
+0.41000.52%
Post-market: 78.50-0.4200-0.53%19:43 EST
Volume:2.24M
Turnover:177.03M
Market Cap:15.26B
PE:-15.20
High:80.44
Open:78.85
Low:78.05
Close:78.51
52wk High:81.49
52wk Low:29.17
Shares:193.32M
Float Shares:165.00M
Volume Ratio:1.03
T/O Rate:1.36%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.1931
EPS(LYR):-3.5776
ROE:-60.76%
ROA:-32.29%
PB:9.55
PE(LYR):-22.06

Loading ...

Deutsche Bank to Move Into Revolut’s Canary Wharf Headquarters - FT

THOMSON REUTERS
·
Dec 06

Revolution Medicines Director and Officer Mark A. Goldsmith Reports Sale of Common Shares

Reuters
·
Nov 27

Revolution Medicines Director and Officer Mark A. Goldsmith Reports Disposal of Common Shares

Reuters
·
Nov 21

U.S. RESEARCH ROUNDUP-Agios Pharmaceuticals, Dycom, Lowe's

Reuters
·
Nov 20

Revolution Medicines Inc : JP Morgan Raises Target Price to $92 From $82

THOMSON REUTERS
·
Nov 20

Jefferies Remains a Buy on Revolution Medicines (RVMD)

TIPRANKS
·
Nov 19

Revolution Medicines Initiated at Outperform by Wolfe Research

Dow Jones
·
Nov 19

Revolution Medicines Director and Officer Mark A. Goldsmith Reports Disposal of Common Shares

Reuters
·
Nov 15

Revolution Medicines CFO Jack Anders Reports Sale of Common Shares

Reuters
·
Nov 14

How Daraxonrasib’s FDA Breakthrough and Orphan Designations Have Changed Revolution Medicines’ (RVMD) Investment Story

Simply Wall St.
·
Nov 09

RBC Capital Keeps Their Buy Rating on Revolution Medicines (RVMD)

TIPRANKS
·
Nov 07

Revolution Medicines Inc : Bofa Global Research Raises Price Objective to $82 From $80

THOMSON REUTERS
·
Nov 06

Revolution Medicines Inc : Needham Raises Target Price to $72 From $66

THOMSON REUTERS
·
Nov 06

Revolution Medicines Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Nov 06

Stock Track | Revolution Medicines Soars 7.48% Pre-market on Multiple Analyst Upgrades

Stock Track
·
Nov 06

JPMorgan ups Revolution Medicines target, adds to Analyst Focus List

TIPRANKS
·
Nov 06

Wedbush Lifts Price Target on Revolution Medicines to $80 From $77, Keeps Outperform Rating

MT Newswires Live
·
Nov 06

Revolution Medicines Inc : Leerink Partners Raises Target Price to $74 From $67

THOMSON REUTERS
·
Nov 06

Revolution Medicines: Promising Growth Trajectory with Strong Financial Health and Strategic Advancements

TIPRANKS
·
Nov 06

Revolution Medicines Unveils Pipeline Advancements Targeting RAS-Driven Cancers

Reuters
·
Nov 06